Qure.ai nets new U.S. FDA clearance for AI software
Summary
Qure.ai has secured FDA clearance for qER-CTA, an AI algorithm that analyzes CT angiography scans for suspected large vessel occlusions. The software is designed to identify occlusions in key brain arteries and help emergency teams triage patients faster. This clearance expands Qure.ai’s regulated software portfolio and gives the company another route to clinical adoption in U.S. hospitals. It also strengthens the company’s position in stroke-imaging workflows where speed and specialist notification matter most.
Classifications
industries
Fintech & Banking
applications
AI & Machine learning
AskAI Classifications
Labels
Healthcare AI
SaaS
Medical Imaging Software
Linked Companies
Qure.ai
$50M to $100M